Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
Monoclonal antibody drug discovery focus
Telephone: +44 (0)1223 833 301
Meditrina (B260) Babraham Research Campus Babraham
Post Code: CB22 3AT
Country: United Kingdom
Membership Type: Corporate 51+